Bespak Secured Nasal Device Access Deal

The company signed an agreement to utilize a compact nasal dry powder delivery device for future medical therapies.

Updated on Oct. 14, 2026 in Asthma

Isometric editorial illustration of a compact medical nasal delivery device, presented in a clean and technical style. — Bespak has finalized a memorandum of understanding with SNBL to gain global access to a compact, single-use nasal dry powder delivery device. AI Illustration. Upload story photo >

Live Poll

Do you believe new delivery technologies improve patient access to necessary medical treatments?

Bespak has finalized a memorandum of understanding with SNBL to gain global access to a compact, single-use nasal dry powder delivery device. This technology, known as the Air Pump Unit Dose Intranasal Powder device, is designed to simplify drug administration for patients.

Why it matters

The partnership aims to strengthen Bespak's ability to offer comprehensive nasal drug delivery solutions. By expanding its portfolio, the company seeks to manage both the development and commercial supply of specialized medical treatments.

The Air Pump Unit Dose Intranasal Powder device is one of only three FDA-approved dry powder nasal devices currently on the market. It utilizes a user-activated air pump to deliver medication without requiring the patient to coordinate breathing.

The players

Bespak

Bespak is a contract manufacturing organization that provides services for the filling and assembly of specialized pharmaceutical products.

SNBL

SNBL is a life sciences company that focuses on the development and evaluation of drug delivery technologies.

The details

The device operates via a drug-containing nozzle that releases powder directly into the nasal passage. Its design specifically removes the need for synchronized inhalation, which can be a significant barrier to effective delivery in traditional nasal sprays.

April 2025: The Air Pump Unit Dose Intranasal Powder device received FDA approval as part of the Atzumi migraine treatment.

The Big Picture

The agreement centers on the Air Pump Unit Dose Intranasal Powder device as a platform for future therapies. This strategy follows a precedent set by the device's own regulatory approval for the Atzumi migraine treatment, signaling its expansion into wider therapeutic applications.

The use of this device may simplify medication routines for patients who struggle with the complex inhalation coordination required by other systems. Because the device does not require synchronized breathing, it could provide a more reliable and user-friendly experience for future treatments.

The takeaway

Advancements in nasal delivery technology are increasingly focusing on reducing the user effort required to successfully administer medication. Patients and providers should monitor how this device is incorporated into new treatments to see if it improves adherence and overall therapeutic efficacy.